Blueprint News1 year ago
New Blood Test Predicts Alzheimer’s Risk and HBOT May Help Lower It
Bryan Johnson shares data showing a 28 percent drop in p-TAU217, a newly FDA-approved marker for early Alzheimer’s risk, following hyperbaric oxygen therapy. Today, we’re sharing...